Gaithersburg, MD, September 30, 2015 – MaxCyte® Inc., the pioneer in cell therapies using scalable, high-performance cell transfection systems, today announces that Chief Executive Officer, Doug Doerfler, is to present at the Immuno-Oncology Conference, part of the Cell Therapy & Commercialization meeting, to be held September 30 – October 1 in Hilton Alexandria Mark Center, Virginia.
Mr. Doerfler will give a presentation entitled “Clinical translation of mRNA CAR engineered Therapeutic Apheresis as targeted therapy for solid tumors.” During his presentation, he will discuss the latest safety and biological activity of CAR mRNA engineered T-cells, obtained from therapeutic apheresis, and their potential in ongoing human clinical trials to target solid tumors.
Please visit //www.ibclifesciences.com/ImmunoOncology/overview.xml for full information about the conference.
The following are specific details regarding Maxcyte’s presentation at the conference:
Event: Cell Therapy Bioprocessing & Commercialization | Immuno-oncology
Date: Thursday, October 1, 2015
Time: 11:00 AM EST
Location: Hilton Alexandria Mark Center, 5000 Seminary Rd, Alexandria, VA 22311
MaxCyte is the leader in driving the next generation of cell-based medicines with flow electroporation. MaxCyte’s best-in-class cell modification technology is used in the discovery, development, and manufacture of small molecule, biologic, and cell-based medicines. The MaxCyte GT® Flow Transfection System, the MaxCyte STX® Scalable Transfection System, and the MaxCyte VLX® Large Scale Transfection System enable the rapid development and consistent production of (co)transfected cells for cellular therapy, genetic engineering, protein and antibody production, rapid response vaccine development, and cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale. In addition to being used in 9 out of the top 10 companies worldwide, MaxCyte currently has clinical, pre-clinical-partnered, and proprietary products under development and is involved in more than a dozen clinical trials.
For more information visit /